Hypervascular Tumors clinical trials at UC Irvine

1 research study open to eligible people

Showing trials for

  • Instylla HES Hypervascular Tumor Pivotal Study

    open to eligible people ages 22 years and up

    To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional transarterial chemoembolization, while resulting in an acceptable risk of device and procedure-related serious adverse events.

    Irvine, California and other locations

Our lead scientists for Hypervascular Tumors research studies include .

Last updated: